Cingulate Posts Wider Loss in Q2
Cingulate (NASDAQ:CING), a biopharmaceutical company focused initially on ADHD and anxiety, released its second-quarter results on August 19, 2025. The company’s most noteworthy milestone was the submission of its NDA to the U.S. Food and Drug Administration for CTx-1301, a once-daily, extended-release medication for attention deficit/hyperactivity disorder (ADHD). Cingulate reported a net loss of $4.8 million (GAAP) as operating expenses spiked, and the reported net loss was deeper than last year’s. Overall, the quarter marked regulatory momentum but underlined the company’s need for new capital as cash reserves continued to decline.
Source: Analyst estimates for the quarter provided by FactSet.
Cingulate is an early-stage biopharmaceutical company that develops therapies for central nervous system disorders. Its main product candidate is CTx-1301, designed as an extended-release tablet for ADHD, targeting both pediatric and adult populations. The company leverages its Precision Timed Release (PTR) drug delivery platform, engineered to combine speed of action with all-day efficacy from a single daily dose.
Source Fool.com
